Kolon TissueGene, Inc. (KOSDAQ:950160)

Kolon TissueGene Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	94,851	67,742	802.87	27,433	41,563	38,813
Short-Term Investments	27,241	14,349	-	-	16,700	200.03
Cash & Short-Term Investments	122,092	82,091	802.87	27,433	58,263	39,013
Cash Growth	129.42%	10124.67%	-97.07%	-52.92%	49.34%	-30.74%
Accounts Receivable	152.14	179.59	237.73	183.58	33.64	334.24
Other Receivables	258.05	422.16	25.84	1,195	700.99	8.56
Receivables	410.18	601.75	263.58	1,378	734.62	342.8
Inventory	24.66	60.48	93.46	64.28	16.56	170.58
Prepaid Expenses	952.82	870.34	1,435	1,283	1,252	1,536
Other Current Assets	3,536	2,668	4,821	1,872	2,804	2,386
Total Current Assets	127,016	86,292	7,415	32,031	63,070	43,449
Property, Plant & Equipment	6,122	6,122	6,971	7,061	8,157	8,945
Other Intangible Assets	232.75	176.92	182.12	126.01	234.49	202.97
Long-Term Deferred Charges	355,526	311,779	200,081	87,539	30,990	5,790
Other Long-Term Assets	21,694	19,621	7,639	8,154	7,439	3,013
Total Assets	510,590	423,990	222,288	134,910	109,890	61,399

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	268.26	305.93	325.38	253.51	102.69	90.35
Accrued Expenses	10,647	11,756	3,200	1,709	2,529	9,901
Short-Term Debt	59,566	74,204	10,894	-	-	-
Current Portion of Leases	1,308	1,213	1,072	907.64	800.14	654.92
Current Unearned Revenue	39.43	39.05	8.95	9	-	-
Other Current Liabilities	309,636	268,164	55,610	11,424	8,172	5,496
Total Current Liabilities	381,465	355,682	71,111	14,303	11,604	16,143
Long-Term Leases	4,119	4,145	5,274	5,568	6,273	6,578
Pension & Post-Retirement Benefits	168.85	82.78	-	-	-	-
Other Long-Term Liabilities	0	-	0	75.75	524.12	31
Total Liabilities	385,752	359,909	76,384	19,947	18,401	22,752

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	2.57	2.39	2.34	1.88	1.75	1.54
Additional Paid-In Capital	887,559	689,576	586,568	470,458	424,164	339,585
Retained Earnings	-762,801	-625,439	-441,532	-355,250	-332,401	-300,732
Comprehensive Income & Other	75.72	-60.5	863.7	-248.43	-277.49	-208.79
Total Common Equity	124,836	64,079	145,902	114,962	91,487	38,646
Shareholders' Equity	124,838	64,081	145,904	114,963	91,489	38,648
Total Liabilities & Equity	510,590	423,990	222,288	134,910	109,890	61,399

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	64,992	79,561	17,240	6,476	7,074	7,233
Net Cash (Debt)	57,100	2,530	-16,437	20,957	51,189	31,781
Net Cash Growth	226.81%	-	-	-59.06%	61.07%	-22.18%
Net Cash Per Share	688.59	30.79	-213.60	292.25	772.24	519.01
Filing Date Shares Outstanding	83.33	83.22	80.04	73.21	69.97	61.91
Total Common Shares Outstanding	83.33	83.22	80.04	73.21	69.97	61.91
Working Capital	-254,449	-269,390	-63,695	17,727	51,466	27,306
Book Value Per Share	1498.12	769.99	1822.92	1570.27	1307.54	624.28
Tangible Book Value	124,604	63,902	145,720	114,836	91,253	38,443
Tangible Book Value Per Share	1495.33	767.86	1820.65	1568.55	1304.18	621.00
Machinery	1,611	1,510	1,035	910.56	965.54	276.33

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 12, 2026

Data Sources Report a data error